Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Astrocytic injury and endothelial activation are interconnected processes within the neurovascular system that may contribute to variability in cognitive performance among cognitively unimpaired adults. Glial fibrillary acidic protein (GFAP) reflects astrocytic injury, while vascular cell adhesion molecule-1 (VCAM-1) reflects systemic endothelial activation. We examined whether VCAM-1 modifies associations between GFAP and cognition in cognitively unimpaired Black adults. This cross-sectional analysis included 313 Black adults aged ≥ 45 years enrolled in the Aging Research Characterizing Health Exposome via Social Drivers (ARCHES) study. Cognitive performance was assessed using the Preclinical Alzheimer Cognitive Composite (PACC) as the primary outcome and the Montreal Cognitive Assessment (MoCA) as a secondary outcome. Plasma GFAP and VCAM-1 were quantified using ultrasensitive immunoassays (NULISA™; Alamar Biosciences). Gaussian generalized linear models tested main effects and a VCAM-1 × GFAP interaction, adjusting for age, sex, and years of education; sensitivity analyses additionally adjusted for the Area Deprivation Index (ADI), body mass index (BMI), and apolipoprotein E (APOE) ε4 genotype. VCAM-1 and GFAP did not show independent associations with PACC; however, the VCAM-1 × GFAP interaction was significant (β = -1.36 × 10⁻⁶, 95% CI: -2.43 × 10⁻⁶ to -2.94 × 10⁻⁷, p = 0.013; FDR p = 0.030; standardized β = -0.118) and remained significant after additional adjustment for ADI, BMI, and APOE ε4 status. Associations were not significant for MoCA. These findings suggest that VCAM-1 may modify the relationship between GFAP and cognitive performance in cognitively unimpaired Black adults.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Singh, R. K., Bekena, S., Walker, A. I. B., Zhu, Y., Trani, J. F., & Babulal, G. M. (2026). Associations among cognitive performance, VCAM-1, and GFAP in black adults: The ARCHES study. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2026.07.003

Vancouver

Singh RK, Bekena S, Walker AIB, Zhu Y, Trani JF, Babulal GM. Associations among cognitive performance, VCAM-1, and GFAP in black adults: The ARCHES study. Neurobiology of Aging. 2026. doi:10.1016/j.neurobiolaging.2026.07.003. PMID: 42431159.

BibTeX

@article{singh2026-42431159,
  author  = {Singh, Ramkrishna K. and Bekena, Semere and Walker, Alexis I. B. and Zhu, Yiqi and Trani, JF and Babulal, Ganesh Muneshwar},
  title   = {{Associations among cognitive performance, VCAM-1, and GFAP in black adults: The ARCHES study}},
  journal = {Neurobiology of Aging},
  year    = {2026},
  doi     = {10.1016/j.neurobiolaging.2026.07.003},
  pmid    = {42431159},
  url     = {https://doi.org/10.1016/j.neurobiolaging.2026.07.003}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this cross-sectional study of 313 cognitively unimpaired Black adults, VCAM-1 and GFAP showed no independent associations with cognitive performance, but their interaction was significant for the primary outcome and not for the secondary outcome. The findings suggest VCAM-1 may modify the relationship between GFAP and cognition, but this is an early cross-sectional result and does not establish any treatment, cure, or prevention.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 4 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 49 of 100.49 of 100 points earned51 not earned

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurobiology of Aging)
Journal's citation record 3 / 4 Neurobiology of Aging: journal h-index 263 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 2 / 4 313 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Ganesh Muneshwar Babulal: h-index 31 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42431159)
Free to read 2 / 2 Free to read
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors

Also tagged “controlled”

1,118 studies in the library carry the topic tag “controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,118 tagged studies.

Similar studies

More on Risk factors

See all studies in Risk factors →